Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

FLUOROURACIL

All products: general benefit

Other products in the same Health Canada class (L01B, L01BC) — coverage varies; not interchangeable

  • Capecitabine (Xeloda): general benefit
  • Mercaptopurine (Purinethol): general benefit
  • Methotrexate (Methotrexate Sodium): general benefit, Not a benefit
  • Thioguanine (Lanvis): general benefit
  • Fludarabine (Fludara): limited Use 424, 379

Efudex · DIN 00330582 · 5% · Cr

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Efudex · DIN 00330582 Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01 Health Canada: Marketed since 2021-06-10 · brand EFUDEX · ATC L01BC02 FLUOROURACIL · form Cream · route Topical · ingredients FLUOROURACIL 5 %/W/W · company Bausch health, canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Efudex: Formulary list price $1.1569/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.1569 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2138 · Verify on the e-Formulary ↗ (DIN 00330582)

Source record
DIN 00330582: Efudex Raw flags: sec3=Y Item: 843600014; group id 862; item number 2084; lccId None; manufacturer id VAL Source form: Cr; strength: 5% Recorded listing: General benefit Source prices (unrounded): $1.1569; ministry $1.1569 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00330582 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=2138
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00330582
Shortage record checked 2026-09-13T08:10:21.292534+00:00

FLUOROURACIL & SALICYLIC ACID

All products: general benefit

Other products in the same Health Canada class (L01B, L01BC) — coverage varies; not interchangeable

  • Capecitabine (Xeloda): general benefit
  • Mercaptopurine (Purinethol): general benefit
  • Methotrexate (Methotrexate Sodium): general benefit, Not a benefit
  • Thioguanine (Lanvis): general benefit
  • Fludarabine (Fludara): limited Use 424, 379

Actikerall · DIN 02428946 · 0.5% w/w & 10% w/w · Top Sol

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Actikerall · DIN 02428946 Manufacturer: Cipher Pharmaceuticals Inc.; listing date 2018-10-31 Health Canada: Marketed since 2016-02-19 · brand ACTIKERALL · ATC L01BC52 FLUOROURACIL, COMBINATIONS, L01BC52 FLUOROURACIL, COMBINATIONS · form Solution · route Topical · ingredients SALICYLIC ACID 10 %/W/W, FLUOROURACIL 0.5 %/W/W · company Cipher pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Actikerall: Formulary list price $2.1304/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.1304 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91338 · Verify on the e-Formulary ↗ (DIN 02428946)

Source record
DIN 02428946: Actikerall Raw flags: sec3=Y Item: 100000288; group id 162; item number 0277; lccId None; manufacturer id CIP Source form: Top Sol; strength: 0.5% w/w & 10% w/w Recorded listing: General benefit Source prices (unrounded): $2.1304; ministry $2.1304 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428946 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91338
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02428946
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSERELIN ACETATE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

MERCAPTOPURINE

· 2 products · General benefit · strengths: 50mg · Tab

METHOTREXATE

· 34 products · General benefit (29), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 20mg/2mL, 50mg/2mL, 10mg/0.2mL, 12.5mg/0.25mL, 15mg/0.3mL, 17.5mg/0.35mL, 20mg/0.4mL, 22.5mg/0.45mL, 25mg/0.5mL, 2.5mg, 10mg · Inj Sol-2mL Pk, Inj Sol-Pref Syr, Tab

THIOGUANINE

· 1 products · General benefit · strengths: 40mg · Tab

FLUDARABINE PHOSPHATE

· 1 products · Limited Use, codes 424, 379 · strengths: 10mg · Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 17 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSERELIN ACETATE

· 4 products · General benefit · strengths: 6.3mg, 9.45mg, 1mg/mL · Implant Kit, Inj Sol-5.5mL Pk, Nas Sp-10mL Pk

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 10:00 and 34 more
Full class listing Related classes:

Other drugs in the same formulary class (84:36 Miscellaneous Skin and Mucous Membrane Agents) and how they are covered

Matched class: 84:36 Miscellaneous Skin and Mucous Membrane Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACITRETIN, AZELAIC ACID, ISOTRETINOIN, ZINC SULFATE Some products covered without a code (check the product listing): COLLAGENASE 84:36 Miscellaneous Skin and Mucous Membrane Agents

ACITRETIN

· 6 products · General benefit · strengths: 10mg, 25mg · Cap

AZELAIC ACID

· 1 products · General benefit · strengths: 15% · Top Gel

COLLAGENASE

· 2 products · General benefit (1), Temporary benefit (1) · strengths: 250Unit/g · 30g Pk, Oint-30g Pk

ISOTRETINOIN

· 8 products · General benefit · strengths: 10mg, 20mg, 30mg, 40mg · Cap

ZINC SULFATE

· 2 products · General benefit · strengths: 0.5%, 10mg · Oint, Sup

ALITRETINOIN

· 4 products · Listed, not a benefit (2), Limited Use, codes 442 (2) · strengths: 10mg, 30mg · Cap

BRODALUMAB

· 1 products · Limited Use, codes 553 · strengths: 210mg/1.5mL · Inj Sol-Pref Syr

CALCIPOTRIOL

· 1 products · Limited Use, codes 191 · strengths: 50mcg/g · Oint

CALCITRIOL

· 1 products · Limited Use, codes 191 · strengths: 3mcg/g · Oint

IXEKIZUMAB

· 2 products · Limited Use, codes 526 · strengths: 80mg/mL · Inj Sol-Pref Autoinj, Inj Sol-Pref Syr

PIMECROLIMUS

· 1 products · Limited Use, codes 383 · strengths: 1% · Cr

RISANKIZUMAB

· 3 products · Limited Use, codes 574 · strengths: 75mg/0.83mL, 150mg/mL · Inj Sol-0.83mL Pref Syr (Preservative-Free), Inj Sol-Pref Pen (Preservative-Free), Inj Sol-Pref Syr (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:36 and 3 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:06 Anti-Inflammatory, 84:28 Keratolytic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS EFUDEX is recommended for the topical treatment of premalignant keratoses and superficial basal cell carcinoma. 1.1 Pediatrics (≥ 18 years of age) Based on the data submitted and reviewed by Health Canada, the safety and efficacy of EFUDEX in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use https://pdf.hres.ca/dpd_pm/00061734.PDF PM date: June 9, 2021 Source product: EFUDEX; DIN 00330582; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE ACTIKERALL (fluorouracil and salicylic acid) is indicated for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients. Grade I/II intensity is based on the 4-point scale of Olsen et al (see CLINICAL TRIALS). Geriatrics (≥ 65 years of age): The clinical trials were mainly performed in patients 65 years and older. Due to the small number of patients <65 years in the clinical trials subgroup analysis of efficacy and safety by age (>65 vs <65 years) has not been conducted (see WARNINGS AND PRECAUTIONS). Pediatrics (< 18 years of age): The safety and efficacy of ACTIKERALL has not been established in the pediatric population. https://pdf.hres.ca/dpd_pm/00032488.PDF PM date: not printed or not captured Source product: ACTIKERALL; DIN 02428946; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.